Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells.

Cancer research - 1 Jan 2020

Finn Kenneth J, Martin Scott E, Settleman Jeff

Abstract excerpt

Despite the remarkable clinical efficacy demonstrated by molecularly targeted cancer therapeutics, the benefits are typically temporary due to the emergence of acquired drug resistance. This has spurred a massive effort by the cancer research community to identify mechanisms used by cancer cells to evade treatment. Among the various methodologies developed and employed to identify such mechanisms, the most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Oncogenes

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 31641034
DOI: 10.1158/0008-5472.CAN-19-0729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells.PMID 31641034Read ↗

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal CancerSemantic proximity Read ↗

Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapiesSemantic proximity Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.Semantic proximity Read ↗

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures.Semantic proximity Read ↗

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressuresSemantic proximity Read ↗

Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.Semantic proximity Read ↗

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal CancerSemantic proximity Read ↗

The emergence of resistance to targeted cancer therapeutics.Semantic proximity Read ↗

Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure.Semantic proximity Read ↗

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read ↗

Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.